# OnCo record denosumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/denosumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "denosumab" ;
  schema:name "Denosumab"@en ;
  schema:alternateName "Wyost"@en, "Jubbonti"@en, "Osenvelt"@en, "Stoboclo"@en, "Xgeva / Prolia" ;
  schema:description "Denosumab is an injection under the skin that blocks the signal driving bone breakdown. As Xgeva it prevents fractures and other bone complications in people whose cancer has spread to bone or who have myeloma; as Prolia it treats osteoporosis, including bone loss caused by hormone therapy for breast and prostate cancer."@en ;
  schema:url <https://onco.cc/drugs/denosumab/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Denosumab> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=denosumab>, <https://www.cancer.gov/about-cancer/treatment/drugs/denosumab>, <https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva> ;
  onco:status "approved" ;
  onco:tag "nci-list", "supportive" ;
  onco:modality "Monoclonal antibody (anti-RANKL, fully human IgG2)" ;
  onco:approval "US 2010: Prevention of skeletal-related events in bone metastases from solid tumours (Xgeva); postmenopausal osteoporosis and treatment-induced bone loss (Prolia)", "US 2013: Giant cell tumour of bone; hypercalcaemia of malignancy (2014); multiple myeloma (2018)", "EU 2011: Prevention of skeletal-related events in bone metastases and, later, multiple myeloma; giant cell tumour of bone (Xgeva)" ;
  onco:related <https://onco.cc/drugs/zoledronic-acid/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/osteosarcoma/> ;
  onco:technologies <https://onco.cc/technologies/bone-modifying-agents/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/rankl/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:terms <https://onco.cc/terms/bone-metastases/> ;
  onco:trials <https://onco.cc/trials/nct07028268/> .